



pharmaceuticals ltd.

Registered & Corporate Office :

Plot No. 19-111, Road No. 71,
Opp. Bharatiya Vidya Bhavan Public School,
Jubilee Hills Hyderabad - 500 096. Telangana. INDIA,
Tel : +91-40-6628 8888, Fax : +91-40-2355 1402
CIN : L24239AP1987PLC008066
Email : info@smspharma.com, www.smspharma.com

Date: 14th February, 2019

To,
The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code: 532815

Symbol: SMSPHARMA

Subject: Outcome of the Board Meeting held on 14th February, 2019: Reg.

Dear Sir/Madam,

With reference to the above cited subject, the Board of Directors of the Company at their meeting held on today i.e., 14th February, 2019 inter-alia has

1) Approved the standalone Un-audited Financial Results for the third Quarter ended 31st December, 2018 along with Limited Review Report.

2) Approved Shifting of the Registered & Corporate office of the Company from the present premises situated at Plot. No. 19-III, Road No. 71, Opp. Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad- 50096 to the new premises with the effect from of 15th February, 2019 situated at Plot. No; 72, H. No; 8-2-334/3&4, Road. No: 5, Banjara Hills, Hyderabad – 500034, Telangana, India. Tel: +91-040-25259999 Fax: +91-040-25259889.

3) Pursuant to SEBI (Prohibition of Insider Trading) Amendment Regulations, 2018 the Board of Director of the Company adopted revised Policy for Fair Disclosure of Unpublished Price Sensitive Information under Regulation 8(1) Chapter IV, which has been amended to incorporate additional clauses mandated by the SEBI (PIT) Amendment Regulations 2018.

4) Pursuant to the securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) (Amendment) Regulations, 2018 the Board of Directors has amended the following polices:

- i) Stakeholders Relationship Committee
- ii) Nomination and Remuneration Committee
- iii) Audit Committee

Accordingly, please find enclosed the;

Standalone Un-audited Financial Results for the third Quarter ended on 31st December, 2018 along with Limited Review Report.


The meeting Commenced at 02.30. PM and concluded at 04.25 pm

Kindly take in to your records.

Thanking you

Yours Faithfully,

For SMS Pharmaceuticals Limited



V.S.Venkatesh

Company Secretary

SMS PHARMACEUTICALS LIMITED

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Statement of Standalone Un-Audited Financial Results for the Quarter and Half Year Ended 31st December, 2018

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Nine Months ended		Year ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	10,125.40	13,484.05	10,371.95	36,120.11	36,362.42	46,486.33
2	Other Income	59.33	148.60	15.64	244.07	169.90	238.79
3	Total Revenue	10,184.73	13,632.65	10,387.59	36,364.18	36,532.32	46,725.12
4	Expenses						
	(a) Cost of Materials Consumed	4,708.43	9,971.38	7,095.47	23,019.79	24,626.64	29,432.23
	(b) Changes in Inventories	1,056.43	(1,269.48)	(1,135.52)	(515.43)	(815.74)	(442.31)
	(c) Central Excise Duty	-	-	-	-	261.58	218.81
	(d) Manufacturing Expenses	670.63	992.25	882.32	2,695.13	2,620.25	3,450.40
	(e) Employee Benefits Expense	909.62	902.97	814.27	2,672.41	2,304.84	3,280.34
	(f) Finance Cost	272.15	295.14	402.21	869.17	1,180.03	1,547.96
	(g) Depreciation and Amortization Expense	482.59	481.92	499.07	1,439.85	1,489.36	1,989.98
	(f) Other Expenses	220.93	354.21	200.94	785.58	754.36	1,212.89
	Total Expenses - (a to f)	8,320.78	11,728.39	8,758.76	30,966.50	32,421.32	40,690.30
5	Profit before Exceptional and Extraordinary Items and Tax (3-4)	1,863.94	1,904.26	1,628.83	5,397.69	4,111.00	6,034.82
6	Exceptional items	-	-	-	-	-	-
7	Profit before Extraordinary Items and Tax (5-6)	1,863.94	1,904.26	1,628.83	5,397.69	4,111.00	6,034.82
8	Extraordinary Items	-	-	-	-	-	-
9	Profit before Tax (7-8)	1,863.94	1,904.26	1,628.83	5,397.69	4,111.00	6,034.82
10	Tax Expenses						
	(1) Current Tax (MAT)	450.00	450.00	350.00	1,250.00	891.64	1,276.15
	(2) Deferred Tax	194.56	198.45	64.49	661.05	144.75	713.24
11	Net Profit / (Loss) for the Period (9-10)	1,219.38	1,255.81	1,214.34	3,486.64	3,074.61	4,045.43
12	Other Comprehensive Income (OCI):						
	Items that will not be reclassified to profit or Loss:	(2.52)	(2.37)	(10.05)	(6.47)	(35.58)	6.31
	Tax on Items that will not be reclassified to profit or Loss:	(0.88)	(0.83)	(3.51)	(2.26)	(12.43)	2.20
		(1.64)	(1.54)	(6.54)	(4.21)	(23.15)	4.11
13	Total comprehensive Income for the period (11+12)	1,217.74	1,254.27	1,207.80	3,482.43	3,051.46	4,049.54
14	Earning Per Equity Share	1.44	1.48	1.43	4.12	3.63	4.78
	(of Re.1/ each) (not annualised)						
	(a) Basic						
	(b) Diluted						
15	Paid-up equity share capital (Face Value of Re.1/- each)	846.52	846.52	846.52	846.52	846.52	846.52
16	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						29,264.04



Notes:

- 1 The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 14th February, 2019 and have been approved by the Board of Directors at its meeting held on 14th February, 2019.
- 2 Results for the quarter ended 31st December, 2018 were subjected to 'Limited Review' by the Auditors.
- 3 The above results are in accordance with the companies (Indian Accounting Standards) rules, 2015, (Ind AS) as amended by Company (Ind AS) (amendment) Rules, 2016, notified under Section 133 of the Companies Act 2013, read with relevant Rules issued there under and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- 4 The Company is engaged in the manufacturing Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 5 As per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.
- 6 Post Implementation of Goods and Service Tax ("GST") with effect from 1 July 2017, revenue from operations is disclosed net of GST. Revenue from Operations for the nine months ended 31 December 2017 and year ended 31 March 2018 includes excise duty up to 30 June 2017 which is now subsumed into GST. Accordingly, revenue from operations for the nine months ended 31 December 2018 is not comparable with nine months ended 31 December 2017.
- 7 Figures of previous period have been regrouped / rearranged wherever necessary.

Place: Hyderabad
Date : 14-02-2019



For SMS Pharmaceuticals Limited


Ramesh Babu Potluri
Chairman and Managing Director



Limited Review Report

To
The Board of Directors
SMS PHARMACEUTICALS LIMITED
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of SMS PHARMACEUTICALS LIMITED ("the Company"), for the quarter ended 31st December 2018 ("the statement"), being submitted by the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July,2016.


This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July,2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 14-02-2019

For Suryanarayana & Suresh.,
Chartered Accountants
Reg. No.006631S


V Nagendra Rao
Partner
M. No. 227679

